We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23
Avg Time Held Equity + Options
6.9 quarters
Top 10 Avg Time Held Equity + Options
4.1 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
7.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
4.5 quarters

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX icon
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
COGT icon
26
Cogent Biosciences
COGT
$4.88B
$65.1M 1.21%
1,681,300
+1,359,200
+422% +$47.6M
2025 Q4
2 quarters
BSX icon
27
Boston Scientific
BSX
$61.8B
$63.3M 1.17%
1,483,200
-898,900
-38% -$48.8M
2014 Q1
49 quarters
ISRG icon
28
Intuitive Surgical
ISRG
$147B
$62.8M 1.16%
157,900
-50,800
-24% -$22.2M
2013 Q4
50 quarters
MLYS icon
29
Mineralys Therapeutics
MLYS
$1.87B
$56.9M 1.06%
2,110,300
+57,400
+3% +$1.57M
2025 Q2
4 quarters
ODTX icon
30
Odyssey Therapeutics
ODTX
$821M
$56.2M 1.04%
+3,001,198
New +$52.6M
2026 Q2
0 quarters
XENE icon
31
Xenon Pharmaceuticals
XENE
$3.3B
$53.9M 1%
892,471
-167,500
-16% -$9.3M
2016 Q3
39 quarters
ARQT icon
32
Arcutis Biotherapeutics
ARQT
$3.36B
$53.5M 0.99%
+2,042,000
New +$47.6M
2026 Q2
0 quarters
BMY icon
33
Bristol-Myers Squibb
BMY
$118B
$53.3M 0.99%
925,000
– –
2025 Q4
2 quarters
QTTB icon
34
Q32 Bio
QTTB
$241M
$52.6M 0.97%
4,127,987
+1,875,000
+83% +$15.7M
2024 Q1
9 quarters
SYK icon
35
Stryker
SYK
$107B
$50.1M 0.93%
159,100
-23,400
-13% -$7.37M
2020 Q3
23 quarters
CAI icon
36
Caris Life Sciences
CAI
$8.71B
$50M 0.93%
2,806,811
– –
2025 Q2
4 quarters
XBI icon
37
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.73B
$47.5M 0.88%
+300,000
New +$40.6M
2026 Q2
0 quarters
TMO icon
38
Thermo Fisher Scientific
TMO
$248B
$45.5M 0.84%
90,700
+44,200
+95% +$21.2M
2013 Q2
52 quarters
PVLA icon
39
Palvella Therapeutics
PVLA
$1.79B
$44.7M 0.83%
292,360
+157,760
+117% +$19.1M
2026 Q1
1 quarter
ELV icon
40
Elevance Health
ELV
$91.8B
$44.4M 0.82%
114,700
– –
2025 Q4
2 quarters
STTK icon
41
Shattuck Labs
STTK
$530M
$43.8M 0.81%
6,306,127
– –
2025 Q3
3 quarters
UPB icon
42
Upstream Bio Inc
UPB
$183M
$39.4M 0.73%
5,693,589
– –
2024 Q4
6 quarters
CRNX icon
43
DELISTED
Crinetics Pharmaceuticals
CRNX
$37.4M 0.69%
999,000
– –
2018 Q3
31 quarters
RYTM icon
44
Rhythm Pharmaceuticals
RYTM
$6B
$35.9M 0.66%
322,900
+8,800
+3% +$796K
2023 Q3
11 quarters
SNDX icon
45
Syndax Pharmaceuticals
SNDX
$1.23B
$33.7M 0.62%
1,542,000
+579,700
+60% +$12.1M
2026 Q1
1 quarter
FBRX icon
46
DELISTED
Forte Biosciences
FBRX
$33.5M 0.62%
1,577,705
+380,750
+32% +$9.03M
2024 Q4
6 quarters
CMPX icon
47
Compass Therapeutics
CMPX
$153M
$33.3M 0.62%
15,219,994
– –
2021 Q4
18 quarters
NKTR icon
48
Nektar Therapeutics
NKTR
$1.27B
$32.5M 0.6%
465,346
+190,346
+69% +$13.9M
2026 Q1
1 quarter
KRYS icon
49
Krystal Biotech
KRYS
$9.65B
$30.9M 0.57%
83,200
+14,100
+20% +$4.21M
2023 Q4
10 quarters
AXSM icon
50
Axsome Therapeutics
AXSM
$8.43B
$28.8M 0.53%
117,578
-96,343
-45% -$20.9M
2025 Q1
5 quarters
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.